Develops drugs for genetic diseases.
Jun 2026Revenue $713M/yrExpenses $1.21B/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will BridgeBio Pharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $713M and expenses $1.21B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $502M | $1.03B | −$523M |
| Dec 2024 | $222M | $815M | −$593M |
| Dec 2023 | $9.30M | $617M | −$607M |
| Dec 2022 | $77.6M | $590M | −$512M |
| Dec 2021 | $69.7M | $646M | −$577M |
| Dec 2020 | $8.25M | $483M | −$474M |
| Dec 2019 | $40.6M | $307M | −$266M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.